Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. The company operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment involves in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers; and provides in vitro products and avian vaccine services. This segment also offers a range of services to assist customers in the drug discovery and development process, which include assistance in the breeding and maintenance of research models; consulting and staffing services; assistance in discovery, research, development, and imaging activities; and research animal diagnostic services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management for the discovery and development of new drugs, devices, and therapies. This segment offers services in the areas of toxicology; pathology services; bioanalysis, pharmacokinetics, and drug metabolism; discovery support; and outsourced testing of biologics and devices. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector & Industry Watch List